<DOC>
	<DOCNO>NCT02351635</DOCNO>
	<brief_summary>The purpose study confirm sensitivity specificity BÜHLMANN fCAL™ ELISA aid diagnosis differentiate Inflammatory Bowel Disease ( IBD ; Crohn 's Disease ( CD ) , Ulcerative Colitis ( UC ) , indeterminate colitis ) Irritable Bowel Syndrome ( IBS ) . To estimate predictive value positive test ( positive predictive value ( PPV ) ) predictive value negative test ( Negative Predictive Value ( NPV ) ) use propose test outcomes BÜHLMANN Calprotectin Test result use patient refer diagnostic evaluation sign symptoms suggestive either IBS IBD . To confirm inter-laboratory consistency test result BÜHLMANN fCAL™ ELISA . To provide exploratory observation test result patient age 2 21 year . To provide sample set normal subject symptoms sign gastrointestinal disease use Expected Value Testing .</brief_summary>
	<brief_title>BÜHLMANN fCAL™ ELISA - Aid Differentiation IBD From IBS</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<criteria>1 . Adults pediatric patient evaluate gastroenterological service investigation possible inflammatory intestinal disease IBS . Patients refer subspecialty evaluation symptom abdominal pain , diarrhea , alter appetite , weight loss , anemia . IBD : Eligible subject analyze patient IBD confirm diagnosis Inflammatory Bowel Disease ( CD , UC , Indeterminate Colitis ) , base endoscopy confirm histology biopsy take endoscopy . IBS : Eligible candidate subject also include patient selfreferred relevant constellation complaint . Eligible subject enrol diagnosis IBS base Rome III criterion confirm negative endoscopy include colon terminal ileum . GI Disorders : Eligible subject enrol diagnosis gastrointestinal disorder IBD IBS , confirm endoscopy result appropriate diagnostic study . Healthy Controls : Adults ( ≥22 ) abdominal complaint history IBS , IBD chronic intestinal disorder , confirm medical history physical examination enrolment . 2 . Individuals either gender , ≥22 year age ( adult sample ) 2 21 year age ( pediatric sample ) . 3 . IBD patient whose diagnostic endoscopy occur within previous month . 4 . Individuals able understand study task require , sign Informed Consent Form ( adult subject ; ICF ) whose parent/guardian provide consent ( ICF ) , age 7to18 year age , provide assent ( pediatric subject ) . 1 . Individuals unable unwilling provide stool specimen . 2 . Individuals know intestinal cancer , intestinal infection , upper gastrointestinal disease 3 . Individuals receive chemotherapy systemic immunosuppressive drug . 4 . Individuals take , within previous 2 week , protein pump inhibitor H2receptor antagonist . 5 . Individuals previously diagnose Inflammatory Bowel Disease manage immunomodulators , 5ASA ( 5aminosalicylic acid ) biologic therapy undergo surgical resection diversion procedure . 6 . Individuals take NSAIDs ( nonsteroidal antiinflammatory drug ) , include aspirin , 7 day 2 week provide sample .</criteria>
	<gender>All</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Calprotectin</keyword>
	<keyword>Diagnosis</keyword>
</DOC>